Fluorescence Detection of Cell Death in Liver of Mice Treated with Thioacetamide

  • Kang, Jin Seok (Department of Biomedical Laboratory Science, Namseoul University)
  • Received : 2017.10.10
  • Accepted : 2017.12.13
  • Published : 2018.01.15


The purpose of this study was to detect cell death in the liver of mice treated with thioacetamide (TAA) using fluorescence bioimaging and compare this outcome with that using conventional histopathological examination. At 6 weeks of age, 24 mice were randomly divided into three groups: group 1 (G1), control group; group 2 (G2), fluorescence probe control group; group 3 (G3), TAA-treated group. G3 mice were treated with TAA. Twenty-two hours after TAA treatment, G2 and G3 mice were treated with Annexin-Vivo 750. Fluorescence in vivo bioimaging was performed by fluorescence molecular tomography at two hours after Annexin-Vivo 750 treatment, and fluorescence ex vivo bioimaging of the liver was performed. Liver damage was validated by histopathological examination. In vivo bioimaging showed that the fluorescence intensity was increased in the right upper part of G3 mice compared with that in G2 mice, whereas G1 mice showed no signal. Additionally ex vivo bioimaging showed that the fluorescence intensity was significantly increased in the livers of G3 mice compared with those in G1 or G2 mice (p < 0.05). Histopathological examination of the liver showed no cell death in G1 and G2 mice. However, in G3 mice, there was destruction of hepatocytes and increased cell death. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining confirmed many cell death features in the liver of G3 mice, whereas no pathological findings were observed in the liver of G1 and G2 mice. Taken together, fluorescence bioimaging in this study showed the detection of cell death and made it possible to quantify the level of cell death in male mice. The outcome was correlated with conventional biomedical examination. As it was difficult to differentiate histological location by fluorescent bioimaging, it is necessary to develop specific fluorescent dyes for monitoring hepatic disease progression and to exploit new bioimaging techniques without dye-labeling.


  1. Okada, H. and Mak, T.W. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer, 4, 592-603.
  2. Krieser, R.J. and White, K. (2002) Engulfment mechanism of apoptotic cells. Curr. Opin. Cell Biol., 14, 734-738.
  3. Schutters, K. and Reutelingsperger, C. (2010) Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis, 15, 1072-1082.
  4. Goldsworthy, T.L., Fransson-Steen, R. and Maronpot, R.R. (1996) Importance of and approaches to quantification of hepatocyte apoptosis. Toxicol. Pathol., 24, 24-35.
  5. Ying, X. and Monticello, T.M. (2006) Modern imaging technologies in toxicologic pathology: an overview. Toxicol. Pathol., 34, 815-826.
  6. Chen, Y., Liang, C.P., Liu, Y., Fischer, A.H., Parwani, A.V. and Pantanowitz, L. (2012) Review of advanced imaging techniques. J. Pathol. Inform., 3, 22.
  7. Huh, Y.M., Jun, Y.W., Song, H.T., Kim, S., Choi, J.S., Lee, J.H., Yoon, S., Kim, K.S., Shin, J.S., Suh, J.S. and Cheon, J. (2005) In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc., 127, 12387-12391.
  8. Provencher, S.W. (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed., 14, 260-264.
  9. Weissleder, R., Tung, C.H., Mahmood, U. and Bogdanov, A., Jr. (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol., 17, 375-378.
  10. von Wallbrunn, A., Holtke, C., Zuhlsdorf, M., Heindel, W., Schafers, M. and Bremer, C. (2007) In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. Eur. J. Nucl. Med. Mol. Imaging, 34, 745-754.
  11. Jung, H.K., Wang, K., Jung, M.K., Kim, I.S. and Lee, B.H. (2014) In vivo near-infrared fluorescence imaging of apoptosis using histone H1-targeting peptide probe after anti-cancer treatment with cisplatin and cetuximab for early decision on tumor response. PLoS ONE, 9, e100341.
  12. Shuhendler, A.J., Pu, K., Cui, L., Uetrecht, J.P. and Rao, J. (2014) Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing. Nat. Biotechnol., 32, 373-380.
  13. Porter, W.R., Gudzinowicz, M.J. and Neal, R.A. (1979) Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J. Pharmacol. Exp. Ther., 208, 386-391.
  14. Kang, J.S., Wanibuchi, H., Morimura, K., Wongpoomchai, R., Chusiri, Y., Gonzalez, F.J. and Fukushima, S. (2008) Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol. Appl. Pharmacol., 228, 295-300.
  15. Muller, A., Machnik, F., Zimmermann, T. and Schubert, H. (1988) Thioacetamide-induced cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp. Pathol., 34, 229-236.
  16. Dashti, H., Jeppsson, B., Hagerstrand, I., Hultberg, B., Srinivas, U., Abdulla, M. and Bengmark, S. (1989) Thioacetamide- and carbon tetrachloride-induced liver cirrhosis. Eur. Surg. Res., 21, 83-91.
  17. Dasgupta, A., Chatterjee, R. and Chowdhury, J.R. (1981) Thioacetamide-induced hepatocarcinoma in rat. Oncology, 38, 249-253.
  18. Kang, J.S., Morimura, K., Salim, E.I., Wanibuchi, H., Yamaguchi, S. and Fukushima, S. (2005) Persistence of liver cirrhosis in association with proliferation of nonparenchymal cells and altered location of alpha-smooth muscle actin-positive cells. Toxicol. Pathol., 33, 329-335.
  19. Peterson, J.D., Labranche, T.P., Vasquez, K.O., Kossodo, S., Melton, M., Rader, R., Listello, J.T., Abrams, M.A. and Misko, T.P. (2010) Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis. Arthritis Res. Ther., 12, R105.
  20. Lederle, W., Arns, S., Rix, A., Gremse, F., Doleschel, D., Schmaljohann, J., Mottaghy, F.M., Kiessling, F. and Palmowski, M. (2011) Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects. EJNMMI Res., 1, 26.
  21. Levin, S., Bucci, T.J., Cohen, S.M., Fix, A.S., Hardisty, J.F., LeGrand, E.K., Maronpot, R.R. and Trump, B.F. (1999) The nomenclature of cell death: recommendations of an ad hoc Committee of the Society of Toxicologic Pathologists. Toxicol. Pathol., 27, 484-490.
  22. Kim, S., Bae, S.M., Seo, J., Cha, K., Piao, M., Kim, S.J., Son, H.N., Park, R.W., Lee, B.H. and Kim, I.S. (2015) Advantages of the phosphatidylserine-recognizing peptide PSP1 for molecular imaging of tumor apoptosis compared with annexin V. PLoS ONE, 10, e0121171.
  23. Hunter, A.L., Holscher, M.A. and Neal, R.A. (1977) Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J. Pharmacol. Exp. Ther., 200, 439-448.
  24. Wang, X., Lu, Y. and Cederbaum, A.I. (2005) Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice. Hepatology, 42, 400-410.
  25. Cernohorsky, P., Kok, A.C., Bruin, D.M., Brandt, M.J., Faber, D.J., Tuijthof, G.J., Kerkhoffs, G.M., Strackee, S.D. and van Leeuwen, T.G. (2015) Comparison of optical coherence tomography and histopathology in quantitative assessment of goat talus articular cartilage. Acta Orthop., 86, 257-263.
  26. Ritsma, L., Vrisekoop, N. and van Rheenen, J. (2013) In vivo imaging and histochemistry are combined in the cryosection labelling and intravital microscopy technique. Nat. Commun., 4, 2366.
  27. Jain, M., Robinson, B.D., Salamoon, B., Thouvenin, O., Boccara, C. and Mukherjee, S. (2015) Rapid evaluation of fresh ex vivo kidney tissue with full-field optical coherence tomography. J. Pathol. Inform., 6, 53.